SG191992A1 - Apolipoprotein aiv as an antidiabetic peptide - Google Patents

Apolipoprotein aiv as an antidiabetic peptide Download PDF

Info

Publication number
SG191992A1
SG191992A1 SG2013054358A SG2013054358A SG191992A1 SG 191992 A1 SG191992 A1 SG 191992A1 SG 2013054358 A SG2013054358 A SG 2013054358A SG 2013054358 A SG2013054358 A SG 2013054358A SG 191992 A1 SG191992 A1 SG 191992A1
Authority
SG
Singapore
Prior art keywords
apolipoprotein
apoa
subject
biologically active
mice
Prior art date
Application number
SG2013054358A
Other languages
English (en)
Inventor
Patrick Tso
Sean Davidson
Stephen Woods
Fei Wang
Original Assignee
Univ Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cincinnati filed Critical Univ Cincinnati
Publication of SG191992A1 publication Critical patent/SG191992A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SG2013054358A 2011-01-19 2012-01-19 Apolipoprotein aiv as an antidiabetic peptide SG191992A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161434196P 2011-01-19 2011-01-19
PCT/US2012/021802 WO2012100010A1 (en) 2011-01-19 2012-01-19 Apolipoprotein aiv as an antidiabetic peptide

Publications (1)

Publication Number Publication Date
SG191992A1 true SG191992A1 (en) 2013-08-30

Family

ID=45755499

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2013054358A SG191992A1 (en) 2011-01-19 2012-01-19 Apolipoprotein aiv as an antidiabetic peptide

Country Status (13)

Country Link
US (2) US9051394B2 (cg-RX-API-DMAC7.html)
EP (1) EP2665485B1 (cg-RX-API-DMAC7.html)
JP (1) JP2014504601A (cg-RX-API-DMAC7.html)
KR (1) KR20140071272A (cg-RX-API-DMAC7.html)
CN (1) CN103391786B (cg-RX-API-DMAC7.html)
AU (1) AU2012207301B2 (cg-RX-API-DMAC7.html)
CA (1) CA2823712A1 (cg-RX-API-DMAC7.html)
EA (1) EA028218B1 (cg-RX-API-DMAC7.html)
ES (1) ES2620404T3 (cg-RX-API-DMAC7.html)
IL (1) IL227207B (cg-RX-API-DMAC7.html)
MX (1) MX342020B (cg-RX-API-DMAC7.html)
SG (1) SG191992A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012100010A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2786584C (en) * 2010-03-12 2017-07-18 Exxonmobil Upstream Research Company Dynamic grouping of domain objects via smart groups
WO2012100010A1 (en) 2011-01-19 2012-07-26 University Of Cincinnati Apolipoprotein aiv as an antidiabetic peptide
WO2013109342A1 (en) 2012-01-19 2013-07-25 University Of Cincinnati Method of treating diabetes using non-glycosylated apolipoprotein a-iv
JP2015524808A (ja) * 2012-07-25 2015-08-27 ユニバーシティ・オブ・シンシナティ アポリポタンパク質ａｉｖを用いたｉ型糖尿病の治療法
JP6033433B2 (ja) * 2012-07-25 2016-11-30 ユニバーシティ・オブ・シンシナティ アポリポタンパク質ａｉｖを用いて高血糖障害を治療する方法
CN112546201A (zh) * 2019-09-26 2021-03-26 中国科学院生物物理研究所 人工脂蛋白颗粒apoA-Ⅳ脂肪体在治疗和/或预防糖尿病中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686605B1 (fr) * 1992-01-27 1994-03-11 Rhone Poulenc Rorer Sa Nouveaux polypeptides, leur preparation et leur utilisation.
AU7242394A (en) 1993-05-28 1994-12-20 Merck & Co., Inc. Method to control appetite and treat obesity
AU2001251245A1 (en) * 2000-04-05 2001-10-23 Genaissance Pharmaceuticals, Inc. Haplotypes of the apoa4 gene
NZ537006A (en) * 2002-05-17 2008-01-31 Esperion Therapeutics Inc The use of apolipoprotein A-I Milano, for the manufacture ofa composition for treating preventing or reducing ischemic reperfusion injury in a tissue or organ
US20100267052A1 (en) * 2006-09-01 2010-10-21 American Type Culture Collection Compositions and methods for diagnosis and treatment of type 2 diabetes
EP2257814B1 (en) * 2008-03-21 2012-08-29 Podiceps B.v. Diagnostic of pre-symptomatic metabolic syndrome
CN101747305B (zh) * 2008-11-28 2014-06-18 中国医学科学院药物研究所 硝克柳胺化合物晶v型、其制法和其药物组合物与用途
WO2012100010A1 (en) 2011-01-19 2012-07-26 University Of Cincinnati Apolipoprotein aiv as an antidiabetic peptide
WO2013109342A1 (en) 2012-01-19 2013-07-25 University Of Cincinnati Method of treating diabetes using non-glycosylated apolipoprotein a-iv
JP2015524808A (ja) 2012-07-25 2015-08-27 ユニバーシティ・オブ・シンシナティ アポリポタンパク質ａｉｖを用いたｉ型糖尿病の治療法
JP6033433B2 (ja) 2012-07-25 2016-11-30 ユニバーシティ・オブ・シンシナティ アポリポタンパク質ａｉｖを用いて高血糖障害を治療する方法

Also Published As

Publication number Publication date
JP2014504601A (ja) 2014-02-24
MX342020B (es) 2016-09-08
CN103391786A (zh) 2013-11-13
AU2012207301A2 (en) 2015-03-26
EP2665485B1 (en) 2017-01-11
AU2012207301A8 (en) 2013-08-29
EA201391063A1 (ru) 2013-12-30
WO2012100010A1 (en) 2012-07-26
US20140005107A1 (en) 2014-01-02
CN103391786B (zh) 2016-06-22
MX2013008374A (es) 2013-12-06
US20150252095A1 (en) 2015-09-10
US9051394B2 (en) 2015-06-09
US9266941B2 (en) 2016-02-23
KR20140071272A (ko) 2014-06-11
AU2012207301B2 (en) 2016-05-19
CA2823712A1 (en) 2012-07-26
EA028218B1 (ru) 2017-10-31
AU2012207301A1 (en) 2013-08-01
EP2665485A1 (en) 2013-11-27
ES2620404T3 (es) 2017-06-28
IL227207B (en) 2019-09-26

Similar Documents

Publication Publication Date Title
US9266941B2 (en) Apolipoprotein AIV as an antidiabetic peptide
CN107921085B (zh) 用于治疗衰老相关病症的方法和组合物
AU2012366182B2 (en) Method of treating diabetes using non-glycosylated apolipoprotein A-IV
KR20200024263A (ko) 고혈당증의 치료 및 예방을 위한 펩타이드
AU2012385960B2 (en) Method of treating hyperglycemic disorders using apolipoprotein AIV
ES2979305T3 (es) Composiciones y métodos para tratar enfermedades metabólicas
JP5447784B2 (ja) マキサディランの部分ペプチドを含む神経因性疼痛の治療剤
US20250114431A1 (en) Compound, composition and methods for lowering circulating glucose
BR112014016734B1 (pt) Composições compreendendo um peptídeo e usos de composições e peptídeos no tratamento médico